Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development

Clare L. Scott, Elizabeth M. Swisher, Scott H Kaufmann

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.

Original languageEnglish (US)
Pages (from-to)1397-1406
Number of pages10
JournalJournal of Clinical Oncology
Volume33
Issue number12
DOIs
StatePublished - Apr 20 2015

Fingerprint

Germ-Line Mutation
Platinum
Ovarian Neoplasms
Mutation
Poly(ADP-ribose) Polymerase Inhibitors
Neoplasms
Ovarian epithelial cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Poly (ADP-Ribose) polymerase inhibitors : Recent advances and future development. / Scott, Clare L.; Swisher, Elizabeth M.; Kaufmann, Scott H.

In: Journal of Clinical Oncology, Vol. 33, No. 12, 20.04.2015, p. 1397-1406.

Research output: Contribution to journalArticle

Scott, Clare L. ; Swisher, Elizabeth M. ; Kaufmann, Scott H. / Poly (ADP-Ribose) polymerase inhibitors : Recent advances and future development. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 12. pp. 1397-1406.
@article{bf41e6eb4c2d4150883673789e8cc7b1,
title = "Poly (ADP-Ribose) polymerase inhibitors: Recent advances and future development",
abstract = "Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.",
author = "Scott, {Clare L.} and Swisher, {Elizabeth M.} and Kaufmann, {Scott H}",
year = "2015",
month = "4",
day = "20",
doi = "10.1200/JCO.2014.58.8848",
language = "English (US)",
volume = "33",
pages = "1397--1406",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Poly (ADP-Ribose) polymerase inhibitors

T2 - Recent advances and future development

AU - Scott, Clare L.

AU - Swisher, Elizabeth M.

AU - Kaufmann, Scott H

PY - 2015/4/20

Y1 - 2015/4/20

N2 - Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.

AB - Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease. Consistent with preclinical studies, ovarian cancers and a number of other solid tumor types occurring in patients with deleterious germline mutations in BRCA1 or BRCA2 seem to be particularly sensitive. However, it is also becoming clear that germline BRCA1/2 mutations are neither necessary nor sufficient for patients to derive benefit from PARP inhibitors. We provide an update on PARP inhibitor clinical development, describe recent advances in our understanding of PARP inhibitor mechanism of action, and discuss current issues in the development of these agents.

UR - http://www.scopus.com/inward/record.url?scp=84929440309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929440309&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.58.8848

DO - 10.1200/JCO.2014.58.8848

M3 - Article

C2 - 25779564

AN - SCOPUS:84929440309

VL - 33

SP - 1397

EP - 1406

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -